

**clarithromycin 125 mg, 187.5 mg, 250 mg granules for oral suspension (ClaroSip) (No. 217/05)**

**Grunenthal Ltd**

**Product Update**

6 January 2006

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

**ADVICE:** following an abbreviated submission

**Clarithromycin as Clarosip<sup>®</sup>** granules for oral suspension is not recommended for use within NHS Scotland for the treatment of acute and chronic infections caused by clarithromycin susceptible organisms.

It uses sip technology, where the granules are contained within a drinking straw. Clarosip<sup>®</sup> incurs a cost premium of up to 20% compared to alternative oral liquid clarithromycin, with no proven advantage in terms of compliance.

**Advice context:**

*No part of this advice may be used without the whole of the advice being quoted in full.*

*This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.*

*This assessment is based on data submitted by the applicant company up to and including 10 November 2005.*

**Chairman  
Scottish Medicines Consortium**